Deeks JJ, Smith LA, Bradley MD: Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: Systematic review of randomised controlled trials. BMJ 2002;325:619.
Furst DE et al: Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: A 12 week multi-center, double blind, dose response study versus placebo and diclofenac. J Rheumatol 2002;29:436.
Knijff-Dutmer EA et al: Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclooxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford) 2002;41:458.
Lago P et al: Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: A randomized controlled trial. Eur J Pediatr 2002;161:202.
Laine L et al: Serious lower gastrointestinal clinical events with non-selective NSAID or coxib use. Gastroenterology 2003;124:288.
Moran EM: Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. J Environ Pathol Toxicol Oncol 2002;21:193.
Niccoli L, Bellino S, Cantini F: Renal tolerability of three commonly employed non-steroidal anti-inflammatory drugs in elderly patients with osteoarthritis. Clin Exp Rheumatol 2002;20:201.
Olsen AMS et al: Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA 2015;313:805.
Ray WA et al: COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071.
Rovensky J et al: Treatment of knee osteoarthritis with a topical nonsteroidal anti-inflammatory drug. Results of a randomized, double-blind, placebo-controlled study on the efficacy and safety of a 5% ibuprofen cream. Drugs Exp Clin Res 2001;27:209.
Slawson D: NSAID Use associated with increased risk of serious bleeding and CV events after MI. Am Fam Physician 2015;92;60.
U.S. Food and Drug Administration: FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. Available at: www.fda.gov/ Drugs/DrugSafety/ucm451800.htm.
Vane J, Botting R: Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J 1987;1:89. http://www.rheumatology. org/I-Am-A/Patient-Caregiver/Treatments/NSAIDs.
Atzeni F et al: Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun Rev 2007;6:8.
Bannwarth B, Kostine M, Poursac N: A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis. Expert Opin Drug Metab Toxicol 2013;9:6.